Cart
sales@molnova.com
Ophiopogonanone A
CAS No. 75239-63-3
Ophiopogonanone A( —— )
Catalog No. M31492 CAS No. 75239-63-3
Ophiopogonanone A has oxygen free radicals(OFRs) scavenging effects, it can scavenge hydroxyl radical(·OH) and hydrogen peroxide(H2O2) in vitro.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 495 | In Stock |
|
| 50MG | Get Quote | In Stock |
|
| 100MG | Get Quote | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameOphiopogonanone A
-
NoteResearch use only, not for human use.
-
Brief DescriptionOphiopogonanone A has oxygen free radicals(OFRs) scavenging effects, it can scavenge hydroxyl radical(·OH) and hydrogen peroxide(H2O2) in vitro.
-
DescriptionOphiopogonanone A has oxygen free radicals(OFRs) scavenging effects, it can scavenge hydroxyl radical(·OH) and hydrogen peroxide(H2O2) in vitro.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayOthers
-
TargetOther Targets
-
Recptor——
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number75239-63-3
-
Formula Weight328.3
-
Molecular FormulaC18H16O6
-
Purity>98% (HPLC)
-
Solubility——
-
SMILES——
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
-
Polygalasaponin V
Polygalasaponin possesses evident anxiolytic and sedative-hypnotic activities and has a relatively safe dose range, which supports the use of Polygala tenuifolia root as an anxiolytic and sedative-hypnotic drug in folk medicine.
-
Lirilumab
Lirilumab (IPH2102) is an antibody against the lethal immunoglobulin-like receptor antibody KIR2D with antitumor activity that enhances the anti-HPV + cervical cancer activity of natural killer cells through VAV1-dependent NF-κB deinhibition.
-
KIRA6
KIRA6 is an effective inhibitor of IRE1α RNase kinase (IC50: 0.6 μM). It can trigger an apoptotic response.KIRA6 (10-1000 nM, 72 hours) strongly compromises the viability of the KIT-dependent cell line HMC-1.1 at the low nM concentration, in a manner that coincided with KIT blockade.
